TICKERNERD
Menu
EOLSEOLSHealthcare · Drug Manufacturers - Specialty & Generic

EOLS Stock Forecast: Evolus, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$7.64
+3.60% on the day

The 6 Wall Street analysts covering Evolus, Inc. hold a median 12-month price target of $13 — +70.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$486.8M
Ticker Nerd rank
86/ 100
Median analyst target
$13
Analysts covering
6
Revenue$84.1M+21.2% y/y
Operating income−$3.3M
Net income−$8.1M
Free cash flow−$4.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.2%
1M
−4.1%
YTD
+14.8%
1Y
+8.5%
From 52W high
−17.9%
From 52W low
+93.8%
$3.94
$9.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EOLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evolus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
86/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Quality
92
Growth
90
Revisions
69
Volatility
69
Momentum
59
Size
53
Accruals
41
Issuance
26

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EOLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EOLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26EOLSHigh $20Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $12Median $13High $20

The green dot is the last close — the median target sits +70.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$13
25 Aug 2026HC Wainwright & Co.ReiteratesBuy—
17 June 2026BTIGReiteratesBuy—
17 June 2026BTIGReiteratesBuy$13
4 Mar 2026BTIGReiteratesBuy—
3 Feb 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026BTIGMaintainsBuy—
13 Jan 2026StifelMaintainsBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
24 Dec 2025NeedhamReiteratesHold—
2 Dec 2025MizuhoMaintainsOutperform—
8 Sept 2025BTIGReiteratesBuy—
6 Aug 2025BTIGMaintainsBuy—
6 Aug 2025HC Wainwright & Co.MaintainsBuy—
6 Aug 2025NeedhamDowngradeHold—
8 May 2025NeedhamReiteratesBuy—
17 Apr 2025BTIGInitiatesBuy—
10 Apr 2025HC Wainwright & Co.ReiteratesBuy—
9 Apr 2025NeedhamReiteratesBuy—
5 Mar 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EOLS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

EOLS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Evolus, Inc. returned +8.5% against +13.2% for the S&P 500, dividends included.

EOLS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26EOLSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EOLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

Evolus, Inc. (EOLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.4×

Cheaper than 93% of US stocks

Price / sales
1.5×

Cheaper than 59% of US stocks

Price / book
−16.0×

Cheaper than 98% of US stocks

EV / EBITDA
−47.5×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
21.2%

Higher than 70% of US stocks

Earnings growth (YoY)
21.2%

Higher than 60% of US stocks

Gross margin
68.0%

Higher than 81% of US stocks

Operating margin
−5.2%

Higher than 27% of US stocks

Net margin
−10.8%

Higher than 19% of US stocks

Returns & dividend
Return on equity
223.5%

Higher than 98% of US stocks

Return on assets
−5.7%

Higher than 31% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Evolus, Inc. (EOLS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evolus, Inc. has a market value of $486.8M and an enterprise value of $606.4M.

  • Revenue in the twelve months to 30 June 2026: $316.5M. The latest quarter grew 21.2% year on year.

  • Net income over the same four quarters: −$34.3M, a −10.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.52.

  • Free cash flow in the twelve months to 30 June 2026: −$21.9M, after $3.6M of capital spending.

  • Shares outstanding: 66.0M.

  • Trailing P/E: −9.4×; forward P/E: 25.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Evolus, Inc. employs 353 people — $897K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

EOLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
EOLSEvolus, Inc.$486.8M86
KMDAKamada Ltd.$473.9M—
AQSTAquestive Therapeutics, Inc.$510.8M56
TLRYTilray Brands, Inc.$409.4M15
IRWDIronwood Pharmaceuticals, Inc.$572.3M100
TKNOAlpha Teknova, Inc.$381.2M94
CGCCanopy Growth Corp.$373.7M—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Evolus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EOLS news & analysis

Evolus to Participate in Upcoming Investor Conferences in New York and London

Business Wire · 28 Oct 2026neutral

Evolus said members of its management team will participate in two upcoming investor conferences in New York and London. At the Stifel Healthcare Conference in New York on November 11, 2026, management is scheduled to take part in a fireside chat and hold investor meetings.

Why it matters — The conferences provide opportunities for investors to hear from Evolus management and meet with the company.

Evolus to Report Third Quarter Financial Results on November 4, 2026

Business Wire · 21 Oct 2026neutral

Evolus announced that it will report its third-quarter 2026 financial results after U.S. markets close on November 4, 2026. Management will host a conference call and live webcast at 4:30 p.m. ET, followed by a question-and-answer session.

Why it matters — EOLS watchers can note when the company will release its quarterly results and discuss them with investors.

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

Business Wire · 14 Oct 2026positive

Evolus announced an option agreement with a privately held company developing a procedure-based, sustained-release injectable treatment for hair restoration. The agreement adds a potential category to its business development pipeline.

Why it matters — EOLS watchers may note the potential expansion into hair restoration, a category described as complementary to Evolus' existing injectables.

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

Benzinga · 2 Oct 2026negative

The U.S. Food and Drug Administration's Office of Prescription Drug Promotion issued a warning letter to Evolus Inc. in September regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs), related to misbranding in social media promotion.

Why it matters — A regulatory warning letter citing misbranding could raise concerns about Evolus's promotional compliance and potential regulatory scrutiny for its key product, Jeuveau.

FAQ

Frequently asked questions about EOLS stock

What is the EOLS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Evolus, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EOLS stock a buy right now?

Of the 6 analysts covering Evolus, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evolus, Inc. 86 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EOLS?

As at 27 Oct 2026, Evolus, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will EOLS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +70.3% from the last close, and Ticker Nerd's factor model ranks Evolus, Inc. 86 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EOLS stock forecast for 2030?

No analyst covering Evolus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EOLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.

How has EOLS stock performed over the past year?

Evolus, Inc. returned +8.5% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evolus, Inc. do?

Evolus Inc. is a performance beauty company focused on the cash-pay medical aesthetics market.

What is the latest news on EOLS?

The most recent item we track (Business Wire, 28 Oct 2026): "Evolus to Participate in Upcoming Investor Conferences in New York and London". Evolus said members of its management team will participate in two upcoming investor conferences in New York and London. At the Stifel Healthcare Conference in New York on November 11, 2026, management is scheduled to take part in a fireside chat and hold investor meetings.

Company

About Evolus, Inc.

Evolus Inc. is a performance beauty company focused on the cash-pay medical aesthetics market. Evolus Inc. markets Jeuveau, a proprietary neurotoxin used by licensed aesthetic practitioners for temporary improvement in the appearance of moderate to severe frown lines, and Evolysse, a collection of injectable hyaluronic acid gel products for facial aesthetic treatment. The company serves practitioners and consumers across the United States and selected international markets, including Canada, Europe, and Australia, with a business model centered on self-pay aesthetic procedures. Evolus Inc. positions its portfolio around non-reimbursed treatments, combining product commercialization, practitioner support, and brand-led marketing within the medical aesthetics industry.

CEO Mr. David Moatazedi · 353 employees · United States · https://www.evolus.com